ArticleKidney international reports2026
Hydrocortisone Use for Septic Shock in Patients With CKD.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with chronic kidney disease (CKD) are at higher risk of septic shock and mortality than the general population. Although hydrocortisone is often used as an adjuvant therapy for septic shock in the general population to improve clinical outcomes, its effectiveness in patients with CKD remains understudied. Methods: We identified a retrospective cohort of patients within TriNetX US collaborative database diagnosed with nondialysis CKD between November 1, 2010 and October 31, 2025 who also developed septic shock. Outcomes of interest within 90 days included all-cause mortality, major adverse kidney events (MAKE) without persistent kidney dysfunction, major adverse cardiovascular or cerebrovascular events (MACCE), mechanical ventilation, hyperglycemia, reinfections, and delirium. Survival analyses and multivariable Cox proportional hazard models were performed. Results: One to 1, we propensity-score matched 13,141 CKD patients with sepsis treated with hydrocortisone with 13,141 CKD patients with sepsis not treated with hydrocortisone. Our cohort had a mean age of 70 ± 12 years and was 46% female, 21% African American, and 5% Hispanic. Most patients had hypertension (95%), were diabetic (63%), and had ischemic heart disease (68%). Mean serum creatinine concentration was 2.3 ± 2.7 mg/dl, mean lactate concentration was 3 mmol/l, and 25% of patients required mechanical ventilation. In this propensity-score matched analysis, more patients died in the group given hydrocortisone than in the group not given hydrocortisone (4263 [32.4%] vs. 3654 [27.8%]) with adjusted hazard ratio (HR) 1.31 (95% confidence interval [CI]: 1.25-1.36). Hydrocortisone group had higher risk of MAKE HR 1.08 (95% CI: 1.05-1.12), MACCE HR 1.19 (95% CI: 1.15-1.24), and mechanical ventilation HR 1.34 (95% CI: 1.27-1.41) but lower reinfections HR 0.88 (95% CI: 0.85-0.91) and no differences in hyperglycemia HR 1.04 (95% CI: 1.00-1.07) and delirium HR 1.07 (95% CI: 1.00-1.14). Conclusion: In this large, national, multicenter retrospective cohort of patients with CKD and septic shock, use of hydrocortisone was associated with increased risk of mortality, cardiorenal, and pulmonary outcomes, but reduced risk of reinfections. These findings warrant more research to rigorously evaluate the effects of hydrocortisone use in septic shock for this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.